PLBIO(SZ:000403) Chang Jiang Shang Bao·2025-09-11 00:05Core Viewpoint - The control of Palin Biotech (000403.SZ) is set to change hands from its current major shareholder, Shengbang Yinghao Investment Partnership, to China National Biotechnology Group, marking a significant shift in ownership and control within the blood products industry [1][2][5]. Group 1: Share Transfer Details - Shengbang Yinghao plans to transfer approximately 200 million shares, representing 21.03% of the total share capital of Palin Biotech, to China National Biotechnology Group for a total consideration of about 4.7 billion yuan, equating to a per-share price of approximately 23.51 yuan, which is a 31.78% premium over the market price of 17.84 yuan as of September 10 [2][3][6]. - Following the completion of this transaction, China National Biotechnology will become the controlling shareholder of Palin Biotech, with China National Pharmaceutical Group as the actual controller [1][2]. Group 2: Strategic Implications - This acquisition is aimed at strengthening the reserve and supply of critical national strategic resources, thereby consolidating the leading position in the blood products industry [1][6][8]. - Following the acquisition, China National Biotechnology is expected to control over 30% of the blood plasma resources in China, with a total of nine blood product production licenses [1][7][8]. Group 3: Company Performance and Growth - Palin Biotech has expanded its plasma collection stations to a total of 38, ranking among the top three in the industry, and is projected to collect over 1,400 tons of plasma in 2024, maintaining its position in the top tier of blood products [1][7]. - Despite a decline in revenue and net profit in the first half of 2025, the company reported a year-on-year increase of approximately 11% in plasma collection volume, totaling over 770 tons [7].